{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-24-000640","form_type":"8-K","ticker":"PDEX","cik":"0000788920","company_name":"PRO DEX INC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.974622+00:00","generated_at":"2026-06-03T01:13:34.549902+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pro-Dex Q3 revenue up 9% to $14.3M; net income falls to $0.19 EPS on investment losses","bullets":["Net sales $14.3M (+9% YoY); operating income $2.2M (+7%) driven by medical device revenue.","Net income $655k ($0.19 diluted EPS) vs $1.6M ($0.45) prior year; decline due to $1.2M unrealized loss on investments.","Nine-month net sales $38.8M (+10%); operating income $4.8M (+16%).","Nine-month net income $540k ($0.15 diluted EPS) vs $5.6M ($1.52) due to $3.8M unrealized investment losses.","CEO Rick Van Kirk says company tracking toward record revenue year; confident in momentum into FY2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-24-000640","json":"https://secwatch.observer/filing/0001079973-24-000640.json","markdown":"https://secwatch.observer/filing/0001079973-24-000640.md","text":"https://secwatch.observer/filing/0001079973-24-000640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/788920/000107997324000640/0001079973-24-000640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/788920/000107997324000640/pdex_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:13:34.549902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b89e6fdac50faa10c964da03ef09cc980b69223","claim":"PRO DEX INC reported third quarter ended March 31, 2024 results: revenue $14.3 million, net income $655,000, or $0.19 per diluted share, EPS $0.19 per diluted share.","evidence_excerpt":"Net sales for the three months ended March 31, 2024, increased $1.2 million, or 9%, to $14.3 million from $13.1 million for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/788920/000107997324000640/0001079973-24-000640-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended March 31, 2024"},{"label":"Revenue","value":"$14.3 million"},{"label":"Net income","value":"$655,000, or $0.19 per diluted share"},{"label":"EPS","value":"$0.19 per diluted share"},{"label":"Result","value":"reported results"}]},{"claim_id":"d38c91557bf9e3f9d94a733697e2965791921819","claim":"PRO DEX INC reported nine months ended March 31, 2024 results: revenue $38.8 million, net income $540,000, or $0.15 per diluted share, EPS $0.15 per diluted share.","evidence_excerpt":"Net sales for the nine months ended March 31, 2024, increased $3.4 million, or 10%, to $38.8 million from $35.4 million for the nine months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/788920/000107997324000640/0001079973-24-000640-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended March 31, 2024"},{"label":"Revenue","value":"$38.8 million"},{"label":"Net income","value":"$540,000, or $0.15 per diluted share"},{"label":"EPS","value":"$0.15 per diluted share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}